Loading...
Docoh

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients.

RIGL stock data

Calendar

2 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.2M 27.2M 27.2M 27.2M 27.2M 27.2M
Cash burn (monthly) (no burn) 4.8M 4.5M 7.06M 4.3M 5.66M
Cash used (since last report) n/a 6.95M 6.51M 10.22M 6.23M 8.19M
Cash remaining n/a 20.25M 20.69M 16.99M 20.97M 19.01M
Runway (months of cash) n/a 4.2 4.6 2.4 4.9 3.4

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
9 Jun 22 Raul R Rodriguez Common Stock Buy Acquire P No No 0.6884 1,000,000 688.4K 1,391,776
20 May 22 Moos Walter H Common Stock Grant Acquire A No No 0 25,000 0 52,222
20 May 22 Moos Walter H Stock Option Common Stock Grant Acquire A No No 2.01 30,000 60.3K 30,000
20 May 22 Lapointe Anthony Gregg Common Stock Grant Acquire A No No 0 25,000 0 50,000
20 May 22 Lapointe Anthony Gregg Stock Option Common Stock Grant Acquire A No No 2.01 30,000 60.3K 30,000
20 May 22 Lyons Gary A Common Stock Grant Acquire A No No 0 25,000 0 50,000
20 May 22 Lyons Gary A Stock Option Common Stock Grant Acquire A No No 2.01 30,000 60.3K 30,000
20 May 22 Hannah Alison L. Common Stock Grant Acquire A No No 0 25,000 0 31,250
20 May 22 Hannah Alison L. Stock Option Common Stock Grant Acquire A No No 2.01 30,000 60.3K 30,000
13F holders Current Prev Q Change
Total holders 168 165 +1.8%
Opened positions 20 26 -23.1%
Closed positions 17 28 -39.3%
Increased positions 51 43 +18.6%
Reduced positions 55 56 -1.8%
13F shares Current Prev Q Change
Total value 410.06M 461M -11.1%
Total shares 136.64M 139.14M -1.8%
Total puts 140.5K 288.7K -51.3%
Total calls 312.9K 254K +23.2%
Total put/call ratio 0.4 1.1 -60.5%
Largest owners Shares Value Change
FMR 24.18M $72.3M -1.6%
BLK Blackrock 16.57M $49.56M +0.1%
Vanguard 9.13M $27.31M +1.2%
STT State Street 7.52M $22.5M -12.2%
IVZ Invesco 5.16M $15.44M -0.0%
Rock Springs Capital Management 4.92M $14.72M +1.3%
Lord, Abbett & Co. 4.41M $13.19M +1.8%
Nuveen Asset Management 4.15M $13.39M -8.1%
Great Point Partners 4M $11.96M -20.0%
Citadel Advisors 3.97M $11.86M +180.3%
Largest transactions Shares Bought/sold Change
Citadel Advisors 3.97M +2.55M +180.3%
Millennium Management 2.5M -2.05M -45.0%
Adage Capital Partners GP, L.L.C. 1.9M +1.81M +1900.0%
Ikarian Capital 2.14M +1.7M +386.4%
Tamarack Advisers 3.25M -1.25M -27.8%
GS Goldman Sachs 626.67K -1.16M -64.9%
HealthInvest Partners AB 0 -1.09M EXIT
STT State Street 7.52M -1.04M -12.2%
Great Point Partners 4M -1M -20.0%
Sio Capital Management 0 -913.62K EXIT

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: Annora, calendar, Caribbean, Circuit, combat, delisted, delisting, distraction, dyspnea, exclusionary, foreclose, Forma, grace, Hetero, inflation, isocitrate, Jersey, Knight, Latin, letter, lien, Mexico, mutated, Nasdaq, olutasidenib, path, pathophysiology, PDUFA, penalizing, pyrexia, regain, revealing, SA, SOFR, sublicensing, synergistic, thethird, unascertainable, unasserted, USA, vi, vigorously, visit, wake
Removed: begun, enrolling, HS, Incrementally, maintained, marketplace, palmoplantar, PPP, presidential, remained, sNDA, suppurativa, switch, topline